Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Increases in B-type natriuretic peptide (BNP) during treatment with lenalidomide in AL amyloidosis.

Literature DB >> 21127185

Increases in B-type natriuretic peptide (BNP) during treatment with lenalidomide in AL amyloidosis.

Umit Tapan, David C Seldin, Kathleen T Finn, Salli Fennessey, Anthony Shelton, Jerome B Zeldis, Vaishali Sanchorawala.

Abstract

Entities: Chemical Disease Gene

Mesh：

Substances：

Year: 2010 PMID： 21127185 DOI： 10.1182/blood-2010-09-305136

Source DB: PubMed Journal: Blood ISSN： 0006-4971 Impact factor: 22.113

Keyword Cloud
Cited

× No keyword cloud information.

14 in total

1. Stem cell transplantation in patients with systemic AL amyloidosis referred for transplant after suboptimal responses to bortezomib-based initial therapy.

Authors: S W Wong; D Larivee; M Warner; K A Sprague; T Fogaren; R L Comenzo
Journal: Bone Marrow Transplant Date: 2017-04-10 Impact factor: 5.483

2. A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis.

Authors: Giovanni Palladini; Paola Russo; Paolo Milani; Andrea Foli; Francesca Lavatelli; Mario Nuvolone; Stefano Perlini; Giampaolo Merlini
Journal: Haematologica Date: 2012-09-14 Impact factor: 9.941

Review 3. Pathophysiology and treatment of cardiac amyloidosis.

Authors: Morie A Gertz; Angela Dispenzieri; Taimur Sher
Journal: Nat Rev Cardiol Date: 2014-10-14 Impact factor: 32.419

4. Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial.

Authors: Shaji K Kumar; Suzanne R Hayman; Francis K Buadi; Vivek Roy; Martha Q Lacy; Morie A Gertz; Jacob Allred; Kristina M Laumann; Leif P Bergsagel; David Dingli; Joseph R Mikhael; Craig B Reeder; A Keith Stewart; Steven R Zeldenrust; Philip R Greipp; John A Lust; Rafael Fonseca; Stephen J Russell; S Vincent Rajkumar; Angela Dispenzieri
Journal: Blood Date: 2012-04-13 Impact factor: 22.113

5. Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis.

Authors: Angela Dispenzieri; Francis Buadi; Kristina Laumann; Betsy LaPlant; Suzanne R Hayman; Shaji K Kumar; David Dingli; Steven R Zeldenrust; Joseph R Mikhael; Robert Hall; S Vincent Rajkumar; Craig Reeder; Rafael Fonseca; P Lief Bergsagel; A Keith Stewart; Vivek Roy; Thomas E Witzig; John A Lust; Stephen J Russell; Morie A Gertz; Martha Q Lacy
Journal: Blood Date: 2012-04-04 Impact factor: 22.113

6. Lenalidomide, melphalan and dexamethasone in a population of patients with immunoglobulin light chain amyloidosis with high rates of advanced cardiac involvement.

Authors: Shira Dinner; Wesley Witteles; Anosheh Afghahi; Ronald Witteles; Sally Arai; Richard Lafayette; Stanley L Schrier; Michaela Liedtke
Journal: Haematologica Date: 2013-05-28 Impact factor: 9.941

Increases in B-type natriuretic peptide (BNP) during treatment with lenalidomide in AL amyloidosis.

1. Stem cell transplantation in patients with systemic AL amyloidosis referred for transplant after suboptimal responses to bortezomib-based initial therapy.

2. A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis.

Review 3. Pathophysiology and treatment of cardiac amyloidosis.

4. Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial.

5. Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis.

6. Lenalidomide, melphalan and dexamethasone in a population of patients with immunoglobulin light chain amyloidosis with high rates of advanced cardiac involvement.

Review 7. Update on treatment of light chain amyloidosis.

8. Bendamustine With Dexamethasone in Relapsed/Refractory Systemic Light-Chain Amyloidosis: Results of a Phase II Study.

Review 9. Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2021.

10. Updates in cardiac amyloidosis: a review.